// App-Quantinova.ai

2317 : Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Researchers

Presenter

  • Jesus F. San-Miguel

Principal Investigators

  • Bruno Paiva

  • Shaji K. Kumar

  • Meletios A. Dimopoulos

  • Thierry Facon

  • Maria-Victoria Mateos

  • Cyrille Touzeau

  • Andrzej Jakubowiak

  • Saad Z. Usmani

  • Gordon Cook

  • Michele Cavo

  • Hang Quach

  • Jon Ukropec

  • Priya Ramaswami

  • Huiling Pei

  • Steven Sun

  • Jianping Wang

  • Maria Krevvata

  • Nikki DeAngelis

  • Christoph Heuck

  • Rian Van Rampelbergh

  • Anupa Kudva

  • Rachel Kobos

  • Ming Qi

  • Nizar Bahlis

Medical Centers

  • Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain

  • Unite de Genomique du Myelome, IUCT-oncopole, Toulouse, France

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Department of Urology, Mayo Clinic, Rochester, MN, Rochester, MN

  • National and Kapodistrian University of Athens, Athens, Greece

  • CHRU de Lille, Service des maladies du sang, Lille, France

  • (University Hospital of Salamanca,Cancer Research Center-IBMCC ,Salamanca,E

  • Hematology Biology, University Hospital Hotel Dieu, Nantes, France

  • The University of Chicago Medical Center, Chicago, IL

  • Levine Cancer Institute, Charlotte, SC

  • HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • University of Melbourne, St. Vincent's Hospital, Victoria, Australia

  • Janssen Global Medical Affairs, Horsham, PA

  • Janssen Research and Development, Titusville, NJ

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, Beerse, Belgium

  • Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Locations

  • Spain

  • France

  • United States

  • Greece

  • United Kingdom

  • Italy

  • Australia

  • Belgium

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved